Cargando…
Belatacept Conversion in Kidney After Liver Transplantation
BACKGROUND. Costimulatory blockade with belatacept has demonstrated long-term benefits in renal transplantation, but de novo use in liver transplant recipients has resulted in increased rejection, graft loss, and death. However, belatacept conversion as a calcineurin inhibitor (CNI) avoidance strate...
Autores principales: | Cristea, Octav, Karadkhele, Geeta, Kitchens, William H., Vasanth, Payaswini, Larsen, Christian P., Badell, Idelberto R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547931/ https://www.ncbi.nlm.nih.gov/pubmed/34712780 http://dx.doi.org/10.1097/TXD.0000000000001229 |
Ejemplares similares
-
Three-year Outcomes After Conversion From Monthly to Every 2-month Belatacept Maintenance Therapy in Kidney Transplant Recipients: Results From a Randomized Controlled Trial
por: Johnson, Aileen C., et al.
Publicado: (2023) -
Longitudinal Evaluation of Cytopenias in the Renal Transplant Population
por: Johnson, Aileen C., et al.
Publicado: (2022) -
De Novo Belatacept in a Kidney-After-Heart Transplant Recipient
por: Schenk, Austin D., et al.
Publicado: (2019) -
Impact of belatacept and tacrolimus on cytomegalovirus viral load control and relapse in moderate and high‐risk cytomegalovirus serostatus kidney transplant recipients
por: Magua, Wairimu, et al.
Publicado: (2022) -
Late Conversion From Calcineurin Inhibitors to Belatacept in Kidney-Transplant Recipients Has a Significant Beneficial Impact on Glycemic Parameters
por: Terrec, Florian, et al.
Publicado: (2019)